Association Between Epidural Analgesia and Cancer Recurrence or Survival After Surgery for Renal Cell Carcinoma: a Propensity Weighted Analysis

Fang-Yu Yen  
Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

Shih-Pin Lin  
Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

Tzu-Ping Lin  
Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Wen-Kuei Chang  
Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

Mei-Yung Tsou  
Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

Kuang-Yi Chang (kychang@vghtpe.gov.tw)  
Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

Research Article

Keywords: epidural anesthesia and analgesia (EA), renal cell carcinoma (RCC), cancer recurrence, weighted analysis, surgery

DOI: https://doi.org/10.21203/rs.3.rs-453037/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Whether epidural anesthesia and analgesia (EA) is beneficial for postoperative cancer outcomes remains controversial and we conducted this historical cohort study to evaluate the association between EA and long-term outcomes following surgery for renal cell carcinoma (RCC). We collected patients receiving RCC surgery from 2011 to 2017 and followed up them until February 2020. Patient attributes, surgical factors and pathological features were gathered through electronic medical chart review. The association between EA and recurrence-free and overall survival after surgery was evaluated using Cox regression models with inverse probability of treatment weighting (IPTW) to balance the observed covariates. The median follow-up time for the 725 included patients was 50 months (interquartile range: 25.3–66.5) and 145 of them (20%) received perioperative EA. We demonstrated EA use was associated with better recurrence-free survival (IPTW adjusted hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.49–0.83, p < 0.001) and overall survival (IPTW adjusted HR: 0.66, 95% CI: 0.49–0.89, p = 0.006) in patients receiving surgical resection for RCC. More prospective studies are needed to verify this connection between EA and superior cancer outcomes after RCC surgery.

Introduction

Although life expectancy is increasing along with the progression and improvement of medical care, cancer remains the leading cause of death around the world and cancer treatment is still a great challenge in contemporary medicine. Surgical intervention is the mainstay for the control and cure of most solid tumors but postoperative local or distant metastasis, which causes 90% of deaths, remains a common reason for morbidity and mortality in cancer patients.

It should be noted that the perioperative period is associated with an increased formation of new metastatic foci and accelerated growth of micrometastatic disease. Surgical procedures themselves also suppress the host's immunity which is inhibiting pre-existing micro-metastases, and manipulation during surgery can disseminate cancer cells which are shed from the primary tumor to the blood stream or lymphatic system intraoperatively. Moreover, surgery can directly activate the hypothalamic-pituitary-adrenal axis and sympathetic nerve system to increase the levels of catecholamine, prostaglandins and acute inflammatory cytokines (interleukin-6, interleukin-8) that further suppress the cytotoxic activity of macrophages and natural killer (NK) cells.

Also, accumulating evidence shows that anesthetic intervention and analgesia could affect the pathophysiological processes associated with long-term cancer outcomes. Since immunity plays a major role in cancer progression, perioperative pain management could be very important for preventing surgery-induced immunosuppression. Perioperative epidural anesthesia and analgesia (EA) effectively attenuate neuroendocrine stress responses related to surgery, they also reduce intraoperative volatile anesthetics and opioid consumption by blocking noxious afferent inputs transmitted to the central nervous system, and further preserve host immunity. Previous studies have demonstrated that
patients with perioperative EA had better prostate, ovarian, colon, gastro-esophageal and breast cancer outcomes compared with those without \(^7,9\). Nevertheless, few studies have investigated the association between EA and postoperative outcomes after surgery for renal cell carcinoma (RCC).

To fill this gap, we hypothesized that EA is beneficial to long-term outcomes after curative surgery for RCC and we conducted this retrospective study to evaluate the association between EA and cancer recurrence or overall survival. We used a novel propensity weighted analysis to promote analytical power and to reduce potential confounding effects by incorporating important prognostic factors in the analysis. Sensitivity analysis using the two other regression approaches was also employed to ensure the consistency of the estimated results.

**Results**

**Patient characteristics**

A total of 725 patients were included in the study. They had a median follow-up interval of 50 with an interquartile range of 25.3 to 66.5 months and of these patients, 145 (20\%) received EA. In the original sample, patients in the EA groups tended to be younger and have a higher chance of receiving open surgery (Table 1). Compared with the non-EA group, more cases in the EA group received surgery before 2015. However, after IPTW the imbalances in these covariate distributions between the two groups were removed (Table 1).
Table 1
Patient Demographics.

|                      | Original data                          | After IPTW                  |
|----------------------|----------------------------------------|----------------------------|
|                      | Non-EA group (n = 580)                | EA group (n = 145)         |
|                      |                                        | SDD                        |
|                      | Non-EA group (n = 725)                | EA group (n = 622)         |
|                      |                                        | SDD                        |
| Age                  | 59 ± 14                                | 56 ± 14                    | 22.06                      | 58 ± 14 | 58 ± 12 | 1.92 |
| BMI                  | 25.65 ± 4.10                           | 25.39 ± 3.84               | 6.60                       | 25.61 ± 4.10 | 25.68 ± 3.81 | 1.86 |
| Charlson comorbidity index | 4.08 ± 1.70                          | 3.79 ± 1.76               | 16.93                      | 4.03 ± 1.69 | 4.13 ± 1.78 | 5.84 |
| Anesthesia time*     | 8.55 ± 0.36                            | 8.57 ± 0.38               | 3.69                       | 8.56 ± 0.36 | 8.58 ± 0.39 | 4.14 |
| Intraoperative blood loss* | 7.65 ± 1.89                          | 8.03 ± 1.93               | 19.82                      | 7.73 ± 1.90 | 7.65 ± 2.05 | 3.75 |
| Sex, male            | 396 (68.3%)                            | 100 (69.0%)               | 1.49                       | 497 (68.6%) | 450 (72.2%) | 8.04 |
| Smoking              | 134 (23.1%)                            | 38 (26.2%)                | 7.21                       | 172 (23.7%) | 151 (24.2%) | 1.13 |
| Surgical year        |                                        |                            |                            | 42.61                      | 9.87 |
| < 2015               | 281 (48.4%)                            | 100 (69.0%)               | 13.09                      | 381 (52.6%) | 358 (57.5%) | 0.07 |
| Packed RBC transfusion | 131 (22.6%)                          | 41 (28.3%)                | 117.12                     | 173 (23.8%) | 148 (23.8%) | 15.73 |
| Laparoscopic or robotic surgery | 321 (55.3%)                         | 12 (8.3%)                 | 437 (60.3%)               | 368 (59.1%) | 2.34 |
| Partial nephrectomy  | 351 (60.5%)                            | 86 (59.3%)                | 2.46                       | 437 (60.3%) | 368 (59.1%) | 2.34 |
| Cancer cell type     |                                        |                            |                            | 12.87                      | 7.46 |
| Clear cell           | 139 (24.0%)                            | 43 (29.7%)                | 182 (25.1%)               | 136 (21.9%) |

Values were mean ± SD or counts (percent), or median (interquartile range). Standardized difference (SDD) is the difference in mean or proportion divided by the pooled standard error, expressed as percentage; imbalance is defined as absolute value greater than 20 (small effect size).

*On base-2 logarithmic scale.

BMI = body mass index; EA = epidural anesthesia and analgesia; IPTW = inverse probability treatment weighting; RBC = red blood cell; SDD = standardized difference.
Recurrence-free survival

The 5-year RFS rates were 81.6% (95% confidence interval (CI): 74.5–88.7%) and 78.7% (95% CI: 74.8–82.6%) in the EA and non-EA groups, respectively. No significant difference in RFS distribution was noted between the EA and non-EA groups (p = 0.408 by log rank test, Fig. 1A). The crude hazard ratio (HR) of the EA group was 0.84 with a 95% CI of 0.55–1.28. However, after IPTW, the weighted Cox regression analysis demonstrated a significant association between the EA and a better RFS (adjusted HR = 0.64, 95% CI: 0.49–0.83; p < 0.001). For sensitivity analysis, multivariable regression analysis identified six independent prognostic factors for cancer recurrence, including perioperative transfusion, anesthesia time, tumor necrosis, capsular invasion, cancer staging and EA (adjusted HR = 0.62, 95% CI: 0.40–0.96, Table 2). Notice that the association between EA and superior RFS was significant in the quintile-stratified analysis (pooled HR = 0.64, 95% CI: 0.40–1.00; p = 0.05).
Table 2
Forward Model Selection for Recurrence-free Survival Before Weighting

|                          | HR  | 95% CI      | p   |
|--------------------------|-----|-------------|-----|
| Epidural analgesia       | 0.62| 0.40 ~ 0.96 | 0.031|
| Anesthesia time*         | 2.12| 1.29 ~ 3.47 | 0.003|
| Packed RBC transfusion   | 1.65| 1.12 ~ 2.42 | 0.010|
| Tumor necrosis           | 2.40| 1.63 ~ 3.54 | < 0.001|
| Capsular invasion        | 1.61| 1.05 ~ 2.47 | 0.030|
| Cancer Stage             |     |             | < 0.001|
| II vs. I                 | 2.69| 1.47 ~ 4.92 | 0.001|
| III vs. I                | 2.55| 1.59 ~ 4.08 | < 0.001|
| IV vs. I                 | 9.90| 5.75 ~ 17.05| < 0.001|

*On base-2 logarithmic scale.

BMI = body mass index; CI = confidence interval; HR = hazard ratio; RBC = red blood cell.

Overall survival

The 5-year OS rates were 86.8% (95% CI: 80.5–93.1%) and 83.8% (95% CI: 80.3–87.3%) in the EA and non-EA groups, respectively. There was no significant association between EA and better OS in the univariate analysis (p = 0.305 by log rank test, Fig. 1B). The crude HR of EA was 0.76 with a 95% CI of 0.45–1.29. EA was significantly associated with superior OS after IPTW (adjusted HR = 0.66, 95% CI: 0.49–0.89; p = 0.006) and in the quintile-stratified analysis (HR = 0.54, 95% CI: 0.31–0.94; p = 0.03). The multivariable analysis identified six independent prognostic factors of OS, including BMI, Charlson comorbidity index, anesthesia time, tumor necrosis, capsular invasion and cancer stage (Table 3). The association between EA and better OS after RCC surgery was not significant after the adjustment for these significant predictors (HR = 0.63, 95% CI: 0.37–1.07, p = 0.09).
### Table 3
Forward Model Selection for Overall Survival Before Weighting

|                      | HR   | 95% CI      | p     |
|----------------------|------|-------------|-------|
| Epidural analgesia   | 0.63 | 0.37 ~ 1.07 | 0.086 |
| BMI                  | 0.93 | 0.88 ~ 0.99 | 0.025 |
| Charlson comorbidity index | 1.17 | 1.06 ~ 1.29 | 0.003 |
| Anesthesia time*     | 3.15 | 1.84 ~ 5.39 | < 0.001 |
| Tumor necrosis       | 2.83 | 1.75 ~ 4.60 | < 0.001 |
| Capsular invasion    | 1.75 | 1.05 ~ 2.91 | 0.031 |
| Cancer Stage         |      |             | < 0.001 |
| II vs. I             | 2.33 | 1.09 ~ 4.96 | 0.028 |
| III vs. I            | 1.78 | 0.99 ~ 3.22 | 0.054 |
| IV vs. I             | 11.44| 6.26 ~ 20.94| 0.000 |

*On base-2 logarithmic scale.

BMI = body mass index; CI = confidence interval; HR = hazard ratio.

---

**Discussion**

In recent decades, perioperative management has been identified as a factor that could impact cancer outcomes by altering the microenvironment and it has been receiving more clinical attention. All tissue trauma, including the sterile dissection carried out by surgeons, and inflammation have been associated with tumor progression. This study demonstrated the hypothetical benefits of perioperative EA for long-term cancer control and survival in patients following RCC resection. To the best of our knowledge, the current study is the largest comparative epidural study to date which has investigated the association between EA and long-term outcomes after RCC surgery.

The current study had several strengths, including a relatively large sample size, and the fact that we took more prognostic and pathologic factors into account. We also used sound analytical approaches such as IPTW and other regression-based sensitivity analyses to ensure the consistency of the estimated results. Charlson comorbidity index was also used to control for the potential influence of comorbidity severity on the outcomes of interest in the analysis. All these efforts were used to try and provide more precise and reliable estimated results to determine the actual association between EA and RFS or OS after curative surgery for RCC.
Although opioids are widely used to control postoperative pain, they are believed to have negative effects on the immune system. The evidence from clinical observational studies indicates that opioids suppress cellular and humoral immunity, promote angiogenesis, and enhance progression of metastatic disease. Overexpression of µ-opioid receptors on cancer cells is observed and associated with angiogenesis and oncogenic signaling. Perioperative EA is administered near the nerve roots to block sensory and sympathetic nerves. It attenuates the neuroendocrine stress responses of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system activation and minimizes volatile agent and opioid consumption. Therefore, it has been suggested that EA preserves immune function and prevents cancer recurrence after curative surgery but previous studies have reported inconsistent results. Zimmitti et al. reported improved RFS but not OS in patients receiving general anesthesia with EA compared to those without after hepatic resection for colorectal liver metastases. However, the study did not take pre-existing medical conditions, perioperative blood transfusion or pathological features into account. Myles et al. found no significant difference in RFS or OS between the EA and non-EA groups following abdominal cancer surgeries in a post hoc review of randomized control trials. A systemic review and meta-analysis revealed a lower risk of OS but not cancer recurrence among patients with perioperative regional anesthesia and analgesia. A recent study compared perioperative systemic analgesia (SA group) with perioperative EA in addition to systemic analgesia (EA group) following surgical resection of localized RCC, which suggested that EA usage was associated with a significantly improved OS but did not significantly impact cancer-specific survival. Accordingly, more prospective studies are needed to elucidate the associations between EA and long-term outcomes after curative cancer surgeries.

During cancer development, circulating tumor cells may leave the primary tumor and form clinically undetectable metastatic foci. Micrometastases remain in an immunologic equilibrium between tumor cell proliferation and host immunity. However, a cascade of local, systemic cellular and humoral inflammation events may reduce the ability of the host immune system to detect and eradicate cancer cells and could help to disseminated cancer cells which survive the host’s defensive mechanisms. Clinical evidence shows that tissue trauma caused during surgery can accelerate subsequent neoplastic disease. Moreover, an experimental trial reported that the more extensive the surgery is, the more potential there is for postoperative inflammation and complications, which further increase the recurrence rate. Some studies have suggested that open cancer surgery was associated with shorter disease-free survival compared with minimally invasive surgery, which limited surgical trauma, however our investigation did not support the beneficial effects of minimally invasive surgery and partial nephrectomy compared with open surgery and radical nephrectomy, respectively. Notice that similar findings were also noted in another two studies which investigated oncological outcomes in patients undergoing minimally invasive surgery compared with open surgery for clinical T2 RCC and locally advanced RCC, respectively. Similar findings were also noted in another study comparing partial or radical nephrectomy for clear cell RCC larger than 7cm.
Interestingly, we also noted that a longer anesthesia time was associated with worse RFS and OS in the stepwise regression analysis. Singh et al. had similar findings in an analysis of minimally-invasive surgeries for endometrial cancer\textsuperscript{19}. In their study, longer operative time was also associated with increased medical, surgical and overall complication rates. In fact, longer anesthesia time, as a surrogate for longer surgical time, may reflect the underlying aggressiveness of the disease or the complexity and difficulty of the surgery, or both. Since we have taken miscellaneous surgical and oncological factors into consideration to reduce confounding effects, anesthesia time is highly suspected as an independent risk factor of cancer recurrence and mortality in patients receiving RCC surgery.

Still, there are other factors which may have an effect on long-term cancer outcomes, including the use of steroids\textsuperscript{10}, nonsteroidal anti-inflammatory drugs\textsuperscript{4,14,15} and systemic lidocaine\textsuperscript{4,10}, hypothermia\textsuperscript{2,10,14}, postoperative infections\textsuperscript{2}, blood transfusions\textsuperscript{2,10}, etc. Red blood cells (RBC) are commonly given to cancer patients before, during or after major surgery for a number of different reasons. Although the value of blood transfusions for saving lives is indisputable\textsuperscript{20}, blood-component therapy can induce negative effects on the recipients' immune system\textsuperscript{21}, a condition called “transfusion-related immunomodulation”\textsuperscript{21,22}. The detrimental effects of immunomodulation are thought to have an association with systemic inflammation\textsuperscript{22,23} and various immunologic changes, including inhibition of cytotoxic cell activity, and immunosuppressive prostaglandin release\textsuperscript{22}. In the sensitivity analysis, we observed that perioperative packed RBC transfusion was associated with a worse RFS in the multivariable regression analysis. Abu-Ghanem et al. also reported that transfusion reduced RFS, cancer-specific survival, and OS in patients undergoing nephrectomy for RCC\textsuperscript{24}. Tsivian et al. found that perioperative blood transfusion was independently associated with worse oncological outcomes for localized RCC after curative surgery and that the recipients were associated with roughly a 2-fold increase in metastatic progression, all-cause and RCC-specific mortality\textsuperscript{25}. Moreover, negative clinical outcomes were also observed in colon\textsuperscript{22,23} and esophageal\textsuperscript{26} cancer patients who received transfusion during curative-intent surgeries. Based on these findings, it has been suggested that blood transfusion can influence the different stages of tumor development including initiation, promotion, malignant conversion, invasion and metastasis\textsuperscript{20}. To reduce the potential confounding of perioperative blood transfusion on the outcomes of interest, the IPTW methodology was used to balance the exposure of transfusion in both the EA and non-EA groups.

The current study had several limitations. First, patients were not randomized to either group, they instead received EA depending on the preference of the patient, the surgeon or the anesthesiologist. Second, the influence of unmeasured covariates such as opioid dose and nonsteroidal anti-inflammatory drugs use on cancer outcomes cannot be evaluated due to a lack of available data. Third, the clinical outcomes of loss to follow-up patients are unknown and the last observed censoring time was used in the analysis, which may have affected the results.

In conclusion, we demonstrated an association between perioperative EA use and better RFS and OS in patients undergoing curative surgery for RCC. Future prospective studies and randomized clinical trials
with careful design are needed to confirm this relationship between EA and cancer outcomes after curative surgery for RCC and to elucidate the underlying mechanisms.

**Methods**

**Setting and patient selection**

The current study was approved by the Institutional Review Board (IRB) of the Taipei Veterans General Hospital, Taipei, Taiwan (IRB-TPEVGH no. 2018-06-009CC, JUL 2018), and written informed consent was waived by the IRB of the Taipei Veterans General Hospital. All methods were performed in accordance with the relevant guidelines and local regulations. Patients who underwent curative surgery for RCC between January 1st 2012 and December 31st 2017, as determined by reviewing the electronic medical records at our hospital, were included in the study. The exclusion criteria were: patients with benign pathological reports, non-RCC, reoperation for metastasis lesions, missing pathological data or perioperative pain management. All included patients were further classified into two groups based on whether they received perioperative EA or not. The reasons why patients did not receive EA included contraindications to EA, failed epidurals and the preference of the anesthesiologist, surgeon or patient, etc. For those who did not receive perioperative EA, intravenous patient-controlled analgesia with morphine was used to control postoperative pain.

**Anesthetic management**

During general anesthesia, induction was typically preceded by intravenous fentanyl 1–3 µg/kg, propofol 1-2.5 mg/kg and a neuromuscular blocking drug of either cisatracurium 0.15–0.2 mg/kg or rocuronium 0.6–1.2 mg/kg to facilitate tracheal intubation. Anesthesia was maintained with sevoflurane 2–3 vol% or desflurane 6–8 vol%. All epidural catheters were inserted at the lower thoracic or high lumbar region (T10-L2). Patients scheduled to receive EA had an epidural catheter implanted preoperatively which was tested using 2% lidocaine 2 mL to ensure it functioned properly. A loading dose of 1-1.5% lidocaine with or without fentanyl 50 µg was given before the surgical incision, and then bupivacaine 0.25% was continuous infused at a rate of 5–10 ml/hour intraoperatively depending on the hemodynamic stability. EA was administered with bupivacaine 0.0625% for postoperative pain management and typically maintained for 48–72 hours. Patients who did not receive EA had intravenous patient-controlled analgesia (PCA) via an ambulatory infusion pump (Gemstar Yellow, Hospira, IL, USA) to deliver morphine with an infusion rate of 0.5-1.0 mg/hour and a bolus dose of 1 mg with a lockout time of 5–10 minutes.

**Postoperative cancer control**

RCC staging was defined according to the American Joint Committee on Cancer 2010 tumor-node-metastasis cancer classification system. After the primary tumor resection, additional surgeries for metastatic disease were performed depending on the lesion locations, including hepatectomy, colectomy, IVC thrombectomy, etc. Postoperative surveillance was performed regularly at an outpatient clinic and followed the National Comprehensive Cancer Network guidelines.
Data collection

We reviewed the patient's electronic medical records and collected their demographic characteristics, including age, sex, body mass index (BMI) and Charlson comorbidity index. We also collected potential risk factors which might affect cancer prognosis, including cancer staging, pathological features (histologic tumor necrosis, capsular invasion, hilar vein invasion, renal sinus invasion), perioperative blood transfusion, minimal invasive or traditional open surgery, partial or radical nephrectomy and smoking. Current disease status and date of death were also obtained from the medical records. Local recurrence or distant metastasis was determined using imaging studies (computed tomography, magnetic resonance imaging, bone scan) or a tissue biopsy. The primary outcome was recurrence-free survival (RFS) which was defined as the time interval between the date of surgery and the discovery date of cancer recurrence or new metastatic foci. The secondary outcome was overall survival (OS), which was defined as the time from the date of surgery to the date of death. All patients were followed until they were lost to follow-up, death or the 29th February 2020, whichever came first. For those without cancer progression, survival times were defined as the corresponding censored observation.

Statistical analysis

All the included patients were classified into one of two groups depending on whether they received EA or not. Continuous and categorical variables are presented as the mean with standard deviation and count with the percentage, respectively. Logarithmic transformation was conducted to reduce the skewness of non-normal continuous variables. Standardized differences were used to evaluate balance in the collected variables between the two groups. The Kaplan-Meier method was used to compare the RFS and OS between the two groups. Univariate Cox regression analysis was also performed to assess the effects of EA and other covariates on RFS and OS. An inverse probability of treatment weighting (IPTW) method based on propensity scores was used to balance the distributions of the collected variables in the EA and non-EA groups and one percent of subjects at the end of weighting distribution were truncated to reduce the impact of large weights on the analytical results. It should be noted that the propensity scores were generated from the logistic regression analysis and were used to estimate the probability of receiving epidurals given the collected variables (Supplementary Info File 1). Weighted Cox regression analysis was applied to evaluate the association between EA and RFS or OS based on IPTW. For sensitivity analysis, all of the patients were further divided into five equal groups using the quintiles of the generated propensity scores and a stratified Cox regression analysis was conducted to obtain a pooled hazard across the five strata to estimate the association of EA with RFS and OS. In addition, multivariable Cox regression analysis with a stepwise model selection process was used to identify independent predictors of RFS and OS and to evaluate their association with EA. The significance level of all hypothesis testing was set at 0.05 and all the statistical analyses were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).

Declarations
Acknowledgments

This study was supported by grants from Taipei Veterans General Hospital, Taipei, Taiwan (V109C-063), the Ministry of Science and Technology, Taipei, Taiwan (MOST108-2511-H-075-001) and the Anesthesiology Research and Development Foundation, Taipei, Taiwan (ARDF10804).

Author contributions

F.Y.Y. Data collection and manuscript preparation; S.P.L. Data verification and interpretation; T.P.L. Data verification and manuscript revision; W.K.C. Statistical review and manuscript revision; M.Y.T. Data collection and manuscript revision; K.Y.C. Study design, data analysis, manuscript preparation and critical content editing.

Additional information

Competing interests statement: The authors declare no competing interests

References

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **68**, 394-424, doi:10.3322/caac.21492 (2018).

2. Tohme, S., Simmons, R. L. & Tsung, A. Surgery for cancer: a trigger for metastases. *Cancer Res* **77**, 1548-1552, doi:10.1158/0008-5472.Can-16-1536 (2017).

3. Gupta, G. P. & Massagué, J. Cancer metastasis: building a framework. *Cell* **127**, 679-695, doi:10.1016/j.cell.2006.11.001 (2006).

4. Kim, R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. *J Transl Med* **16**, 8, doi:10.1186/s12967-018-1389-7 (2018).

5. Shakhar, G. & Ben-Eliyahu, S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? *Ann Surg Oncol* **10**, 972-992, doi:10.1245/as0.2003.02.007 (2003).

6. Tai, Y. H. et al. The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: a retrospective cohort study. *PLoS One* **13**, e0200893, doi:10.1371/journal.pone.0200893 (2018).

7. Chang, W. K. et al. Does epidural analgesia improve the cancer outcome in hepatocellular carcinoma after resection surgery? a retrospective analysis. *J Chin Med Assoc* **82**, 295-299, doi:10.1097/jcma.0000000000000054 (2019).

8. Kovac, E., Firoozbakhsh, F., Zargar, H., Fergany, A. & Elsharkawy, H. Perioperative epidural analgesia is not associated with increased survival from renal cell cancer, but overall survival may be improved: a retrospective chart review. *Can J Anaesth* **64**, 754-762, doi:10.1007/s12630-017-0875-3 (2017).
9. Sun, Y., Li, T. & Gan, T. J. The effects of perioperative regional anesthesia and analgesia on cancer recurrence and survival after oncology surgery: a systematic review and meta-analysis. *Reg Anesth Pain Med* **40**, 589-598, doi:10.1097/aap.000000000000273 (2015).

10. Wall, T., Sherwin, A., Ma, D. & Buggy, D. J. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: a narrative review. *Br J Anaesth* **123**, 135-150, doi:10.1016/j.bja.2019.04.062 (2019).

11. Lin, J. X. *et al.* Age-adjusted Charlson Comorbidity Index (ACCI) is a significant factor for predicting survival after radical gastrectomy in patients with gastric cancer. *BMC Surg* **19**, 53, doi:10.1186/s12893-019-0513-9 (2019).

12. Zimmitti, G. *et al.* Positive impact of epidural analgesia on oncologic outcomes in patients undergoing resection of colorectal liver metastases. *Ann Surg Oncol* **23**, 1003-1011, doi:10.1245/s10434-015-4933-1 (2016).

13. Myles, P. S. *et al.* Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. *bmj* **342**, d1491, doi:10.1136/bmj.d1491 (2011).

14. Hiller, J. G., Perry, N. J., Poulougiannis, G., Riedel, B. & Sloan, E. K. Perioperative events influence cancer recurrence risk after surgery. *Nat Rev Clin Oncol* **15**, 205-218, doi:10.1038/nrclinonc.2017.194 (2018).

15. Hogan, B. V., Peter, M. B., Shenoy, H. G., Horgan, K. & Hughes, T. A. Surgery induced immunosuppression. *Surgeon* **9**, 38-43, doi:10.1016/j.surge.2010.07.011 (2011).

16. Lee, H. *et al.* Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (≥7cm). *PLoS One* **13**, e0191786, doi:10.1371/journal.pone.0191786 (2018).

17. Bragayrac, L. A. *et al.* Outcomes of minimal invasive vs open radical nephrectomy for the treatment of locally advanced renal-cell carcinoma. *J Endourol* **30**, 871-876, doi:10.1089/end.2016.0082 (2016).

18. Simone, G. *et al.* Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis. *World J Urol* **35**, 789-794, doi:10.1007/s00345-016-1923-2 (2017).

19. Singh, S., Swarer, K. & Resnick, K. Longer operative time is associated with increased post-operative complications in patients undergoing minimally-invasive surgery for endometrial cancer. *Gynecol Oncol* **147**, 554-557, doi:10.1016/j.ygyno.2017.09.024 (2017).

20. Fischer, D., Neb, H., Choorapoikayil, S., Zacharowski, K. & Meybohm, P. Red blood cell transfusion and its alternatives in oncologic surgery - a critical evaluation. *Crit Rev Oncol Hematol* **134**, 1-9, doi:10.1016/j.critrevonc.2018.11.011 (2019).

21. Goubran, H., Sheridan, D., Radossevic, J., Burnouf, T. & Seghatchian, J. Transfusion-related immunomodulation and cancer. *Transfus Apher Sci* **56**, 336-340, doi:10.1016/j.transci.2017.05.019 (2017).

22. Aquina, C. T. *et al.* Association among blood transfusion, sepsis, and decreased long-term survival after colon cancer resection. *Ann Surg* **266**, 311-317, doi:10.1097/sla.0000000000001990 (2017).
23. McSorley, S. T. et al. Perioperative blood transfusion is associated with postoperative systemic inflammatory response and poorer outcomes following surgery for colorectal cancer. *Ann Surg Oncol* **27**, 833-843, doi:10.1245/s10434-019-07984-7 (2020).

24. Abu-Ghanem, Y., Zilberman, D. E., Dotan, Z., Kaver, I. & Ramon, J. Perioperative blood transfusion adversely affects prognosis after nephrectomy for renal cell carcinoma. *Urol Oncol* **36**, 12.e15-12.e20, doi:10.1016/j.urolonc.2017.09.006 (2018).

25. Tsivian, M. et al. Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma. *Urol Oncol* **36**, 362.e361-362.e367, doi:10.1016/j.urolonc.2018.04.014 (2018).

26. Boshier, P. R. et al. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. *Dis Esophagus* **31**, doi:10.1093/dote/dox134 (2018).

27. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* **17**, 1471-1474, doi:10.1245/s10434-010-0985-4 (2010).

28. Stewart, S. B. et al. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. *J Clin Oncol* **32**, 4059-4065, doi:10.1200/jco.2014.56.5416 (2014).

29. Charlson, M., Szatrowski, T. P., Peterson, J. & Gold, J. Validation of a combined comorbidity index. *J Clin Epidemiol* **47**, 1245-1251 (1994).

30. Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med* **34**, 3661-3679, doi:10.1002/sim.6607 (2015).

**Figures**

![Graph A](image1.png)

![Graph B](image2.png)
Figure 1

Kaplan-Meier curves for cancer recurrence and all-cause mortality of EA (epidural anesthesia and analgesia) and non-EA groups. No significant difference in cancer recurrence (Figure 1A) or all-cause mortality (Figure 1B) was found after renal cell carcinoma resection between the EA with non-EA groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryInfoFile1.pdf